SCHEDULE: Oaktree Funds Exit Indivior Stake

Oaktree-managed funds have significantly reduced their holdings in Indivior Pharmaceuticals, Inc., indicating a potential exit from their investment.

Summary

• Several Oaktree-managed funds have filed an amendment to their Schedule 13D, reporting a substantial reduction in their beneficial ownership of Indivior Pharmaceuticals, Inc. common stock.
• The reporting persons, including Oaktree Value Opportunities Fund, L.P., Oaktree London Liquid Value Opportunities Fund (VOF), L.P., and others, have disposed of a significant number of shares and convertible notes.
• As of August 11, 2026, the aggregate beneficial ownership of shares issuable upon conversion of notes is 909,053, representing 0.76% of the outstanding common stock.
• This filing serves as an exit filing, indicating that the reporting persons have ceased to be beneficial owners of more than five percent of the common stock as of August 10, 2026, with further sales on August 11, 2026, prompting this amendment.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant sales activity indicating a potential exit or reduced confidence in the issuer's future performance.

Negatives

• Significant sales of Indivior Pharmaceuticals, Inc. common stock and convertible notes by Oaktree-managed funds.
• The reporting persons have ceased to be beneficial owners of more than five percent of the common stock as of August 10, 2026.
• The filing is characterized as an 'exit filing', suggesting a complete divestment or a substantial reduction in investment.

Risks

• The substantial sales by Oaktree-managed funds could signal a lack of confidence in Indivior's future prospects, potentially impacting investor sentiment.
• Further sales on August 11, 2026, indicate a continued reduction in holdings, which may put downward pressure on the stock price.

Future Outlook

The filing indicates a significant reduction in holdings by Oaktree-managed funds, serving as an exit filing, which suggests a lack of positive future outlook from these investors.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the reported securities, and the filing of this Statement shall not be construed as an admission of such beneficial ownership for the purposes of Section 13(d) or 13(g) of the Exchange Act or for any other purpose.

Industry Context

StockSavvy.ai notes that significant divestments by major investment funds like Oaktree can signal shifts in market sentiment or strategic reallocations, potentially influencing other investors' decisions regarding pharmaceutical and biotechnology companies.

Stakeholder Impact

• Shareholders may experience negative sentiment due to the significant sell-off by a major investment fund, potentially leading to a decrease in share price.
• Creditors and other debt holders might view the exit as a sign of reduced confidence in the company's ability to meet its obligations.

Next Steps

• The reporting persons have completed their exit from the beneficial ownership threshold requiring this filing.

Key Dates

Recommendation

The substantial reduction in holdings and the 'exit filing' status by Oaktree-managed funds suggest a lack of confidence in Indivior Pharmaceuticals' future performance, warranting a sell recommendation for investors.

Keywords

Indivior Pharmaceuticals, Schedule 13D, Oaktree, Convertible Notes, Beneficial Ownership, Stock Sales, Investment Fund